SIAP
ADCT icon

Sterling Investment Advisors (Pennsylvania)’s ADC Therapeutics ADCT Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,100
Closed -$9K – 153
2022
Q2 		$9K Hold
1,100
– – ﹤0.01% 407
2022
Q1 		$16K Hold
1,100
– – ﹤0.01% 383
2021
Q4 		$22K Buy
+1,100
New +$26.5K 0.01% 354
2020
Q3 		– Sell
-1,000
Closed -$46K – 429
2020
Q2 		$46K Buy
+1,000
New +$38K 0.02% 220

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $901M AUM 28.6% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s ADCT Position: Q3 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of ADC Therapeutics (ADCT) in Q3 2022, closing a stake of 1,100 shares — an estimated $9K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in ADCT in Q2 2020 and held it in 4 quarters. The position peaked at $46K in Q2 2020. 66 funds tracked by Wall St. Rank hold ADCT as of Q3 2022.

  • Sterling Investment Advisors (Pennsylvania) reported no remaining ADC Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Sterling Investment Advisors (Pennsylvania) sold 1,100 ADC Therapeutics shares in Q3 2022, an estimated $9K.
  • Sterling Investment Advisors (Pennsylvania) first reported a position in ADC Therapeutics in Q2 2020 and held it in 4 quarters.
  • Sterling Investment Advisors (Pennsylvania)'s ADC Therapeutics position peaked at $46K in Q2 2020.
  • 66 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.